| NICE / U.K. / 02/2008 |
As the exclusive therapeutic recommendation for low risk PCa |
| Nederlandse Vereniging voor Urologie [Dutch urological association] / 07/2007 |
As an equally valid therapeutic option for localized PCa |
| American Urological Association /USA / 2007 |
As a licensed therapeutic option for localized PCa |
| Duodecim, Finnish Medical Society /Finland / 2007 |
As an equally valid therapeutic option for low risk PCa (T1–2, Gleason = 6, PSA = 10) |
| European Urological Association 2007 |
As a licensed therapeutic option for low risk PCa |
| Association française de l’Urologie (French urological association) / France / 2006 |
As a licensed therapeutic option for low risk PCa |
| Sociedade Brasileira de Urologia (Brazilian urological association) / Brazil / 06/2006 |
As an equally valid therapeutic option for low risk PCa |
